Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Premature Birth, Obstetric Labor, Premature
Interventions: Family Nurture Intervention, Standard Care; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 26 Weeks to 34 Weeks
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: New York, New York • San Antonio, Texas

Conditions: Acute Migraine
Interventions: Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo (matches lasmiditan doses); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 92
States / cities: Birmingham, Alabama • Chandler, Arizona • Fountain Hills, Arizona + 67 more

Conditions: Colorectal Cancer
Interventions: Epi proColon Test, Fecal Immunochemical Test (FIT); Device
Lead sponsor: Epigenomics, Inc; Industry
Eligibility: 50 Years to 76 Years
Enrollment: 490 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Portland, Oregon • Danville, Pennsylvania

Conditions: Ileus
Interventions: Ipamorelin, placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Inhaled PT001, Inhaled Placebo, Tiotropium Handihaler; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 6
States / cities: Peoria, Arizona • Denver, Colorado • Miami, Florida + 3 more

Conditions: Premature Birth
Interventions: Interpregnancy Care; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 13 Years to 44 Years · Female only
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 3
States / cities: Jackson, Mississippi

Conditions: Acute Pain, Chronic Pain
Interventions: Dexamethasone, Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 55 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Amlodipine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 139
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more

Conditions: Fibromyalgia Syndrome
Interventions: Lacosamide, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 25
States / cities: Litchfield Park, Arizona • Santa Ana, California • Walnut Creek, California + 21 more

Conditions: Intentional Self-Harm by Other Specified Means
Interventions: Lethal Means Counseling, Health and Stress Reduction; Behavioral
Lead sponsor: University of Southern Mississippi; Other
Eligibility: 18 Years to 60 Years
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Overweight, Obesity
Interventions: Cagrilintide, Placebo cagrilintide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Conyers, Georgia • Honolulu, Hawaii • Oak Park, Illinois + 8 more

Conditions: Renal Transplantation
Interventions: Enteric-coated Mycophenolate Acid (EC-MPA), Mycophenolate Mofetil (MMF), Placebo MMF, Placebo EC-MPA; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 37
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 28 more

Conditions: Gingival Recession
Interventions: Geistlich Fibro-Gide, Connective Tissue Graft (CTG; Device · Procedure
Lead sponsor: Geistlich Pharma AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Fenton, Michigan • Houston, Texas • Tacoma, Washington

Conditions: Cocaine Dependence
Interventions: Community Reinforcement Approach; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Macular Edema
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 48
States / cities: La Jolla, California • Redlands, California • Santa Maria, California + 44 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Texting for Relapse Prevention (T4RP); Behavioral
Lead sponsor: Center for Innovative Public Health Research; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Obesity
Interventions: Group phone counseling, Newsletter; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Up to 75 Years · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Ocular Hypertension
Interventions: Not listed
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hip Pain
Interventions: Ultrasound guided injection; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Osteoarthritis, Knee
Interventions: Pentosan Polysulfate Sodium twice weekly, Placebo; Drug
Lead sponsor: Paradigm Biopharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 41
States / cities: Peoria, Arizona • Tucson, Arizona • Anaheim, California + 34 more

Conditions: Rheumatoid Arthritis
Interventions: CP-690,550, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 24
States / cities: Upland, California • Clearwater, Florida • Miami, Florida + 19 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Lispro Mixture Therapy, Glargine Basal-Bolus Therapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 44
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 41 more

Conditions: Generalized Anxiety Disorder
Interventions: Quetiapine Fumarate, Escitalopram oxylate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 63
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 60 more

Conditions: Stroke, Dysphagia
Interventions: Mendelsohn Maneuver; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 21 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

Family Nurture Intervention in the NICU

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:

Adherence to Minimally Invasive Testing

Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Interpregnancy Care Project-Mississippi (IPC-M)

Dexamethasone and Pain Following Total Knee Arthroplasty

Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Comparison of Lethal Means Counseling and an Active Control Condition, With and Without Provision of Gun Locks

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months

Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Texting for Relapse Prevention

Rural Women Connecting for Better Health

Intraocular Pressure During Robotic Assisted Laparoscopic Procedures Utilizing Steep Trendelenburg Positioning

Comparison of Ultrasound-guided Intraarticular Hip Injections With and Without Prior Local Anesthesia

A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

Treatment of Dysphagia Using the Mendelsohn Maneuver